These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 6183193)

  • 1. Biological Response Modifiers Programme and cancer chemotherapy.
    Oldham RK
    Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologicals and biological response modifiers: fourth modality of cancer treatment.
    Oldham RK
    Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological response modifiers.
    Oldham RK
    J Natl Cancer Inst; 1983 May; 70(5):789-96. PubMed ID: 6188871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer therapy by biological response modifiers.
    Herberman RB
    Arzneimittelforschung; 1987 Feb; 37(2A):246-50. PubMed ID: 2436633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NCI preclinical screen of biological response modifiers.
    Talmadge JE; Fidler IJ; Oldham RK
    Behring Inst Mitt; 1984 May; (74):189-94. PubMed ID: 6206841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of clinical trials with biological response modifiers.
    Herberman RB
    Cancer Treat Rep; 1985 Oct; 69(10):1161-4. PubMed ID: 2412692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Present status of studies on the application of immunology to the diagnosis and therapy of cancer, with emphasis on monoclonal antibodies and cytokines].
    Tokunaga T
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 2):1358-66. PubMed ID: 3296954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges.
    Shen RN; Lu L; Kaiser HE; Broxmeyer HE
    In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers.
    Talmadge JE; Oldham RK; Fidler IJ
    J Biol Response Mod; 1984; 3(1):88-109. PubMed ID: 6707701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of biological responses: what to measure and when.
    Maluish AE; Herberman RB
    Cancer Treat Rep; 1985 Oct; 69(10):1165-9. PubMed ID: 3899356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future directions in the therapy for large bowel cancer.
    Carter SK
    Cancer; 1982 Dec; 50(11 Suppl):2647-56. PubMed ID: 6182979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Methods for evaluating biological response modifiers].
    Harousseau JL
    Bull Cancer; 1998 Dec; 85(12):993-6. PubMed ID: 9917552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic activity in cancer of IL-2 in combination with other cytokines.
    Truitt GA; Brunda MJ; Levitt D; Anderson TD; Sherman MI
    Cancer Surv; 1989; 8(4):875-89. PubMed ID: 2701733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer.
    Oldham RK; Thurman GB; Talmadge JE; Stevenson HC; Foon KA
    Cancer; 1984 Dec; 54(11 Suppl):2795-806. PubMed ID: 6437660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve immunotherapy drugs that could cure cancers.
    Cheever MA
    Immunol Rev; 2008 Apr; 222():357-68. PubMed ID: 18364014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.